Neumora Therapeutics (NMRA) Shares Outstanding (Weighted Average) (2022 - 2026)

Neumora Therapeutics' Shares Outstanding (Weighted Average) history runs 5 years deep, the most recent figure standing at $179.9 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) rose 11.41% year-over-year to $179.9 million; the TTM figure through Mar 2026 stood at $179.9 million (up 11.41% YoY), while the FY2025 annual figure was $163.4 million, up 2.52% from the prior year.
• Shares Outstanding (Weighted Average) was $179.9 million for Q1 2026 at Neumora Therapeutics, up from $163.4 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $179.9 million in Q1 2026 to a low of $27.2 million in Q4 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $112.6 million across 5 years, with a median of $159.0 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Weighted Average) jumped 439.48% in 2024, then gained 1.42% in 2025.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $27.2 million in 2022, then soared by 138.99% to $65.0 million in 2023, then soared by 145.12% to $159.4 million in 2024, then grew by 2.52% to $163.4 million in 2025, then advanced by 10.09% to $179.9 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $179.9 million (Q1 2026), $163.4 million (Q4 2025), and $161.8 million (Q3 2025), per Business Quant data.